Method for early prevention of gestational complications |
|
|
IPC classes for russian patent Method for early prevention of gestational complications (RU 2530624):
Diagnostic technique for renal functional reserve / 2528903
Invention refers to medicine. Substance of the early diagnostic technique for chronic renal disease consists in using a dosage range of dopamine of 1 to 3 mcg/kg of body weight and a standard water load of 200 ml. No glomerular filtration rate increase testifies to the presence of early signs of chronic renal disease.
Diagnostic technique for clinically latent hypercorticoidism in patients suffering from stype 2 diabetes mellitus or obesity / 2521387
First stage comprises a night suppressive test with dexamethasone 1 mg with a test considered to be positive, if plasma cortisol measured at 8.00 in the next morning exceeds 50 nmole/l. If the first stage has a positive result, the second stage is performed 1-2 days later. At the second stage, blood plasma cortisol at 24.00, daily urine free cortisol, a coefficient of circadian rhythm of cortisol secretion are determined on the same day. If at least two of the three test results are above normal: plasma cortisol at 24.00 is more than 207 nmole/l, daily urine free cortisol is more than 180 mcg/day, coefficient of circadian rhythm of cortisol secretion is more than 50%, hypercorticoidism syndrome is diagnosed. The presented technique provides higher accuracy and simplifies diagnosing of the given disease.
 Solid phase enzyme-immunoassay (eliza) for vascular endothelial growth factor (vegf) / 2517301
Invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.
Method for determining degree of severity of chronic obstructive pulmonary disease / 2516971
Blood is examined. The steroid hormones cortisol (nmole/l) and DHEA-S (mcmole/l), as well as the oxidative stress values - oxidative modified proteins (OMP, nM/mg, protein), malondialdehyde (MDA, nM/ml) and SH groups mg% are evaluated. The forced expiratory volume 1(%) FEV1 is calculated by formula on the basis of the derived values. If the derived FEV1 is within 50% to 80%, the presence of a moderate degree of chronic obstructive pulmonary disease; the FEV1 being within the range of 30 to 49% means a severe degree of chronic obstructive pulmonary disease (COPD), and the derived value being less than 30% shows an extremely severe degree of COPD.
Method for prediction of risk of early development of atherosclerosis in patients with chronic prostatitis / 2504782
Blood serum of the younger patient suffering chronic prostatitis is examined for total testosterone, sex hormone-binding globulin to calculate a free testosterone index; high-density lipoproteins and triacylglycerides are determined, and an atherogenic index is calculated by formula. If the atherogenic index is <3.7, a high risk of the early development of atherosclerosis is predicted.
 Method for prediction of recurrent non-small-cell lung cancer / 2498305
What is involves is the histological examination of tissue fragments taken from the extracted lung with primary, intermediate and segmental bronchi at 4-5 cm from the tumour, and disregeneration change cases are determined in the respiratory bronchial epithelium, including: basal cell hyperplasia (BCH), squamous metaplasia (SM) and if observing a combination of basal cell hyperplasia and squamous metaplasia (BCH+SM+) in the respiratory bronchial epithelium adjacent to the tumour, a risk of developing the recurrent non-small-cell lung cancer is predicted.
 Method for prediction of recurrent cervical cancer / 2485523
Method for prediction of recurrent cervical cancer involves biochemical daily urine analysis to determine daily urine androsterone and etiocholanolone to be related; if the relation is 0.75 mg/day or less, the recurrent disease is predicted for the first 2 years, and if the relation exceeding 0.75 mg/day, a prolonged recurrence-free period up to 10 years or more is predicted.
 Method for aromatase activity test / 2481587
Blood serum is examined for lutropin, follitropin, oestradiol, total testosterone and free testosterone levels before and 48 hours after the oral administration of 450 aromatase inhibitor, letrozole 10 mg, and the variations of lutropin and follitropin, as well as of the oestradiol/total testosterone and oestradiol/free testosterone relations are used to asses aromatase activity in points assigned by a certain way to consider low aromatase activity shown by total score 0 to 7 points, normal aromatase activity - 8 to 14 points, and high aromatase activity - 15 points or more.
Method for specifying directionality of pathological process in mucinous gastric carcinoma / 2480771
In males with mucinous gastric carcinoma after a curative resection to the extent of gastrectomy, tumor tissue is analysed for the level of testosterone. If the tissue value is 7.8±0.6 ng/g, process generalisation within 6 to 12 months is predicted; the level of tissue testosterone 174.5±15.6 ng/g enables predicting the favourable clinical course of the process, prolongation of the patient's life.
Method for prediction of recurrent endometrial polyps in postmenopausal women / 2478959
Transvaginal echography in the patients suffering endometrial polyps is conducted to measure an M-echo thickness, mm, the presence of obesity (Ob), blood follicle-stimulating hormone (FSH), IU/l, oestradiol (E2), pg/l; an insulin-resistance index is calculated by HOMA technique; a therapeutic strategy (ThStra) is taken into consideration; a probability of developing recurrent endometrial polyps (p) 1 year after the operation is determined by formula. If the probability exceeds 0.7, a high risk of recurrence is predicted. The probability falling within the range of 0.5 to 0.7 shows a moderate risk, while the probability of 0 to 0.5 shows a low risk.
Method for evaluating risk of developing cardiovascular complications in females suffering from hypertensive disease / 2530621
Invention presents a method for evaluating a risk of developing cardiovascular complications in females suffering from the hypertensive disease by blood sampling from the patients, blood measuring for interleukin-α, receptor interleukin-1 antagonist by the immunoenzyme technique differing by determining a value equal to a relation of the receptor interleukin-1 to interleukin-1α antagonist, a leukemia blood cell inhibition factor and a CD34 cell count that is followed by diagnosing developing cardiovascular complications for the following 5 years with stating a high, medium or low risk of developing complications.
Method for prediction of therapeutic efficacy of severe bronchial asthma / 2530616
Method involves determining an integral cytokine index as a total arithmetical mean of pro-inflammatory interleukin indices and anti-inflammatory interleukin indices. The cytokine concentration is determined at the moment of aggravation of severe bronchial asthma and after an arrest thereof. The pro-inflammatory cytokines IL-2, IL-4, IL-6, IL-8, TNF-α, INF-γ and the anti-inflammatory cytokines IL-10 are detected for allergic and steroid-dependent severe bronchial asthma. The pro-inflammatory cytokines IL-2, IL-6, IL-8, TNF-α, INF-γ and the anti-inflammatory cytokines IL-4, IL-10 are detected for non-allergic bronchial asthma. If a difference of the integral cytokine index calculated at the moment of aggravation of severe bronchial asthma and the integral cytokine index after the arrest is 1 standard unit or more, a possibility to achieve the high efficacy of the basic anti-inflammatory therapy of severe bronchial asthma is predicted; if the difference is less than 1 standard unit, the basic therapy is predicted to be low-effective.
Method for prediction of overall survival in patients suffering from liver metastases of colorectal cancer following hepatic resection / 2530610
Invention refers to a method for the prediction of a total survival in the patients with liver metastases of colorectal cancer following hepatic resection, involving determining clinical-pathological (morphological), histological and molecular prediction factors , differing by the fact that the immunohistochemical method is used to study molecular characteristics of the tumour microenvironment, namely the presence and number of vessels with smooth muscle actin in their wall for the liver metastasis stroma in three visual fields; the visual fields are specified by the maximum immunohistochemical reaction of each section of the liver biopsy material with the metastatic tumour, and if observing the vessels with smooth muscle actin in their wall in each visual field, the patient is referred to a group with a favourable prognosis (the three or more years survival after hepatic resection); with no vessels having the smooth musculature in their wall in all the three visual fields, the patient is referred to a group of the unfavourable prognosis (the survival of less than two years).
 Method of obtaining intermolecular conjugate for immunochromatographic determination of specific antibodies / 2530560
Invention relates to immunology and biotechnology. In immunochromatographic test-systems along with an analytic zone, intended for binding an analysable compound, usually, applied is a control zone, intended for binding the compound, conjugated with a label. The application of the control zone is necessary to control the functional activity of a reagent, conjugated with the label. If colouring of the control zone is absent, the result of the test is considered invalid. However, in case of the application of immunochromatography for determination of antibodies in blood with the label conjugated is a compound, intended for binding antibodies - further designated as CBAn (compound, binding antibodies). The concentration of antibodies in a sample often exceeds the concentration of CBAn, that is why the concentration of free molecules of CBAn is very low and the disappearance of the control zone in this case does not testify to the malfunction of the conjugate activity. To solve the said problem the claimed invention proposes to add antispecies antibodies against the antibodies sorbed in the control zone, to the conjugate In this case the control zone disappears only in case of loss of the CBAn activity. The antispecies antibodies are added in concentrations considerably lower than the binding ability of the conjugate, in order not to interfere with the interaction of the conjugate with the sample antibodies, as a result of which no considerable reduction of analysis sensitivity is observed.
 Differential diagnostic technique for malignant and benign breast pathology / 2530557
Peripheral blood dead cells are treated with primary oestrogen-binding protein antibodies specifically interacting with segmented granulocyte superficial antigens; secondary anti-species fluorescent-labelled antibodies are added to the antigen-antibody complex; the malignant new growths are diagnosed if the segmented granulocyte surface is reported to be stained; no dye stains on the segmented granulocyte surface enable diagnosing benign new growths. The method is non-invasive, enables fast and 100%-accurate differentiation of the patients suffering from breast cancer and the patients with benign new growths and healthy women.
 Recombinant single-domain antibody able to bind human tumour necrosis factor specifically and its derivatives / 2530553
Invention refers to immunology and biotechnology. What is presented is a single-domain antibody (VHH) able to bind the cytokine human necrosis factor (TNF), a DNA fragment coding the antibody according to the invention, as well as a method for identifying the human TNF and measuring it in a biological sample.
Diagnostic technique for viral involvement of vegetative parasympathetic ganglia of head / 2529795
Patient's blood is analysed for the content of specific IgG herpes simplex virus type 1 and cytomegalovirus antibodies, as well as for the content of interferon alpha and interferon gamma. If the content of specific IgG herpes simplex virus type 1 antibodies falls within the range of 1:2973.75 to 1:3058.25, the content of cytomegalovirus antibodies falls within the range of 1:2916.91 to 1:2997.37, the content of interferon alpha is from 178.56 to 194.78 unit/ml, the content of interferon gamma is from 14.37 to 16.87 unit/ml, the herpes viral involvement of the vegetative parasympathetic ganglia of the head is diagnosed.
Diagnostic technique for viral involvement of vegetative parasympathetic ganglia of head / 2529794
Immunoassay of patient's oral fluid is conducted to determine the concentration of secretory immunoglobulin A and interferon alpha. If the oral fluid concentration of secretory immunoglobulin falls within the range of 184.81 to 225.11 mg/ml, while the concentration of interferon alpha falls within the range of 3.94 to 66 mg/ml, the herpes viral involvement of the vegetative parasympathetic ganglia of the head is diagnosed.
Method for assessing acute somatic pain / 2529793
Invention refers to medicine, namely to traumatology and anaesthesiology, and can be used for assessing a patient's posttraumatic acute somatic pain. That is ensured by measuring patient's blood cytokines: interleukin-2 (IL-2), pg/ml, interleukin-4 (IL-4), pg/ml and interleukin-6 (IL-6), pg/ml. Provided the two conditions are observed together: 110.03≤IL-2≤120.37, 127.57≤IL-4≤133.03 and 137.65≤IL-6≤148.75, a degree of pain sensitivity under the effect of a traumatic factor is considered to require prescribing narcotic analgesic.
Method for assessing anti-herpetic efficacy in vitro of photodynamic exposure on herpes simplex virus (hsv) / 2529792
Method involves photodynamic exposure on a Vero cell culture of HSV-1 and HSV-2 infected African green monkey's kidney, on samples containing HSV-1 and HSV-2 and on a virus progeny; if observing a decrease of virus titre from a reference by 2 and more of lg TCD50/0.1 ml in the cell culture, samples containing the viruses, and in the virus progeny, the anti-herpetic action is considered to be effective.
 Method for predicting the character of bacterial keratitis flow / 2245553
In lacrimal liquid one should detect the content of interleukin 8 (IL-8) and that of interleukin 1 beta (IL-1β) to calculate prognostic coefficient (PC) due to dividing the first value by the second one by the following formula:
|
FIELD: medicine. SUBSTANCE: method involves detecting a threatening miscarriage and a carrier state of the polymorphism in the gene of folate metabolism, as well as a CD54+ lymphocyte ratio, lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) levels in venous blood of a pregnant woman from the onset of pregnancy to the end of the first trimester. That is followed by calculating a prognostic index (PI) by formula: PI=0.7199X1+1.2552X2-0.00653X3-0.0009X4+0.0722X5+1.1277, wherein X1 is the threatening miscarriage, yes/no (1/0); X2 is the polymorphism in the gene of folate metabolism, yes/no (1/0); X3 is the CD54+ lymphocyte ratio, %; X4 is the lactoferrin level, ng/ml; X5 is the concentration of the free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml. If PI<0, the gestational complications are predicted, while PI>0 enables stating a low risk of pathological conditions accompanying pregnancy. A sensitivity of the presented method makes 81.2%, its specificity is 85.1%. The method effectiveness is 83.2%. EFFECT: method is minimally invasive, enables identifying a risk group of the gestational complications early that makes it possible to implement preventive measures aiming at preventing the pathological course of the pregnancy. 5 ex
Scope: the present invention relates to medicine, namely to laboratory diagnosis. The level of technology The basis for the formation of various gestational complications is the influence of unfavorable factors, among which the most important are stress, premorbid background factors infectious nature, hormonal disorders, genetic component, etc. However, if you have the same risk factors for the development of pathological conditions is not implemented in all cases. On the other hand, pathological conditions during pregnancy are developing not only in women with high-risk groups (in the presence of somatic and/or obstetric history), but also in healthy women, since pregnancy in some cases is a trigger pathological processes. At the present stage of development of fundamental and clinical medicine scientific research early molecular markers of gestational complications is limited to a differentiated approach to the prediction of some diseases: a number of studies devoted to the prediction of miscarriage mainly in the early stages of pregnancy (like underdeveloped or spontaneous abortion), the other part of the work - preclinical diagnosis of later complications, the man who Pistacia which takes place in the second half of gestation (placental insufficiency, syndrome of delayed fetal growth, pre-eclampsia, preterm birth and other). The disadvantage of such a narrow approach is the underestimation of the risk of formation of pathological conditions, regardless of the duration of pregnancy, which requires the development and introduction into clinical practice algorithm for the early prediction of gestational complications, allowing you to answer the question whether the pregnancy to occur physiologically. Studies of the role of immunological factors in the etiology and pathogenesis of gestational complications does not lose its relevance. Implementation of pathological conditions during pregnancy is the result of many reasons, which together define the type of impaired immune regulation. When significant violations of the immunological mechanisms of regulation of insolvency processes placentation associated with poor differentiation of the trophoblast, causes abortion. If the violation immunological regulation is accompanied by the activation of compensatory mechanisms aimed at limiting the adverse, including embryotoxic effects, it is non-critical violation of trophoblast invasion and partial conversion of vessels of fetoplacental complex that contributes to the preservation and progression take is nasty. In this case, as a rule, depleted placental blood flow does not allow to fully meet the needs of the fetus necessary resources, which leads to the manifestation of various pathological conditions [1, 2]. Thus, in some cases inadequate response of the maternal immune system to the factors of fetal-placental origin leads to irreversible event (termination of pregnancy by type of underdeveloped or spontaneous abortion), mediated by involvement in the pathological process of the vascular component; compensation of irregularities formed a special type of regulation, contributing to the preservation of pregnancy, however, insufficient for the full development of the fetus [2]. Since the evaluation of certain parameters individually has a low information content, perspectives of scientific research in this direction associated with the selection from the totality of risk factors the most significant predictors, the definition of which is at the preclinical stage, the different gestational complications may serve as an early indicator of trouble in the system mother-placenta-fetus " and a reflection of violations of maternal-fruit interactions. Existing methods for predicting gestational complications have a number of disadvantages. The use of a number of methods for predicting outcomes of pregnant the minute it is assumed only in the second half of gestation (when fully developed placenta, visualization of fetal-placental circulation, the threat of a late miscarriage or premature birth), which is not always possible to take preventive measures to prevent the formation of pathological conditions[3, 4, 5, 6, 7]. A number of methods for predicting pregnancy outcomes associated with their use in relation to a particular group of women, which significantly narrows the range of the subject and reduces the value of the developed technology. Thus, known methods of predicting pregnancy outcome in women with recurrent pregnancy loss and high perinatal risk [8, 9], the methods of prediction of early reproductive loss when there is a threat of termination of pregnancy [10, 11], infectious factors [12, 13], giperandrogenii [14], hormonal disorders fetoplacental complex [15], existing abortion in history [12, 16], the methods for predicting complications of pregnancy and development of perinatal pathology in patients with thrombophilia [17], HIV-infected women [18], as well as pregnancy-induced assisted reproductive technologies in connection with the treatment of infertility [19], which in itself is often a condition for inclusion of patients at risk for adverse pregnancy outcomes. These factors both in isolation and in combination with each other could the t to determine violations of the processes of implantation and placentation, as well as hemodynamic changes in mediating the result of deficiencies in the system "mother-placenta-fetus". Narrowly focused approach to predicting pregnancy outcomes, limited or specific pathological condition, or the method of prognosis in a certain contingent of women is not possible to assess the risk of implementation of gestational complications in General, what is the most popular as patients with complicated obstetric history, and pervoverhovnyh women. In this regard, the most valuable are safe (non-invasive or minimally invasive) methods for predicting pregnancy outcomes regardless of the type of pathology and gestation periods tool that lets because of its nonspecific in regard to these factors of nature from an early date, to differentiate physiological and complicated pregnancy. Analogs of this invention are the above-mentioned methods for predicting pregnancy outcomes. In addition to the aforementioned disadvantages of these methods (the use of a certain contingent of women, the definition of indicators in the second half of gestation, the prediction of one specific pathological conditions), the imperfection of the existing methods due to: the complexity caused by the use of special software (for example, "Spectr") your registration file CARDIORHYTHM, as well as a large number of additional calculations based on the indicators of kardiointervalografii and machine with the calculation of frequency bands, spectral variants of HRV and others [5, 20], multi phases of the research, based on the definition of indicators before and after carrying out functional tests, load tests or courses of therapy [5, 6, 11], the complexity of the interpretation of the results for doctors without specialization, the use of unsafe chemicals (including trichloroacetic and hydrochloric acids) and the need to provide special conditions for work with such reagents (equipment exhaust box etc) [21], the use of cumbersome algorithms examination including collection of anamnestic data, not only the mother but also the father, viral load and spectrum of viral antigens in the presence of infection factor, the evaluation of the results of ultrasonic and diplomaticheskii studies summary count prognostic index [16, 18]. A prototype of the proposed invention is a method for predicting pregnancy outcomes, which consists in determining the parties preferential location of the placenta by two-dimensional ultrasonic scanning and counting the relative content of the cells in capillary blood women [4]. Despite the obvious advantages of the prototype method (availability definitions mentioned indicators for any medical practical institutions of the relevant profile, includes standard equipment, as well as the high accuracy of the forecast), the disadvantages of this method include the inability to predict adverse pregnancy outcomes with early deadlines, because visualization of the localization of the placenta is only possible from the second trimester of pregnancy. In addition, the authors predict complications during pregnancy, if the content of the peripheral blood lymphocytes of 20% or less, however, the development of pathological conditions during pregnancy are not always accompanied by a decrease in the number of lymphocytes, and therefore the sensitivity and specificity of the method of prediction, based on the determination of these two parameters, in some cases, low. As a result of generalization of experience and years of research conducted in the fgbi "Ural research Institute of maternity and infancy" of the Ministry of health of the Russian Federation identified the predictors of high risk of occurrence of gestational complications, which represents a typical markers of various pathological conditions, regardless of nosological units (interrupt pregnant the barb-type underdeveloped or spontaneous abortion, placental insufficiency, delayed fetal growth and other perinatal pathology). The invention The aim of the invention is to develop a method of early prediction of implementation of gestational complications, which consists in determining the existence of a threat of termination of this pregnancy and carriage gene polymorphisms in folate metabolism, as well as assessing the relative content of CD54+-peripheral blood lymphocytes, the level of lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) in serum during the period from the time of pregnancy until the end of the first trimester, followed by the calculation of the predictive index (PI). The method is as follows. Fence peripheral venous blood for testing should be performed on an empty stomach in the morning, and in two test tubes in a test tube with anticoagulant (EDTA) in an amount of 0.5 ml in a clean, dry test tube in an amount of 3 ml test Tube with EDTA are used to determine the relative content of CD54+lymphocytes method of flow cytofluorimetry. The second tube is used to produce by centrifugation of the blood serum, which carried out the determination of the level of lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) enzyme-linked immunosorbent assay in accordance with instrukcijem manufacturers. Measurement of the optical density of the samples performed by immunoassay analyzer "SUNRISE" company "TECAN" (Austria). The values obtained based on the data of the history of women (threat of termination of this pregnancy and carriage Homo - or heterozygous mutations in genes of folate metabolism) is used to calculate the prognostic index (PI) according to the formula developed using the method of discriminant analysis: PI=0,7199X1+1,2552X2-0,00653X3-0,0009X4+0,0722X5+1,1277, where X1- presence/absence of the threat of termination of this pregnancy (1/0); X2- presence/absence of gene polymorphisms in folate metabolism (1/0); X3the relative content of CD54+-blood lymphocytes, %; X4- the level of lactoferrin, ng/ml; X5the concentration of free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml When PI<0 predict the implementation of gestational complications, and with PI>0 make a conclusion about the low risk of developing pathological conditions during pregnancy. The sensitivity of the proposed method is 81,2%, specificity of 85.1%. The effectiveness of the method is to 83.2%. Example 1. Fesun SM history No. 8096). The patient was examined in outpatient research clinic NII OMM Ministry of health of Russia 17.09.2010, Avtomobilnaya, perforada. Di is the prognosis: singleton pregnancy 4-5 weeks, habitual miscarriage, hyperprolactinemia, microadenoma pituitary, the carrier of the herpes simplex virus, cytomegalovirus. Signs of threatened abortion no, the woman is a carrier of the gene mutations in folate metabolism: MTRR A66G - G/G (heterozygote), MTHFR AS - a/C (heterozygote), MTR A2756G - A/G (heterozygote). The laboratory examination of blood obtained the following indicators: the relative content CD54+lymphocytes - 23%, the level of lactoferrin -2115 ng/ml, the concentration of β-HCG to 10.2 ng/ml Prognostic index, calculated by the formula, equal -0,286, the negative value of the index indicates a high risk of implementation of gestational complications, and therefore the patient was referred to the risk of development of pathological conditions during pregnancy. The patient was observed in accordance with the standard of medical care to pregnant women in the period of 6-7 weeks for the results of ultrasound examination revealed regressing pregnancy, about which the patient was admitted to the gynecology Department of the Institute, where 30.09.2010 conducted clinical diagnostic curettage of the uterine cavity. In the evaluation of karyotype abortive material chromosomal abnormalities have been identified, which excludes the possibility of interruption in the early stages due to a genetic disorder. Example 2. Volod the so-CALLED Cova. (history of births No. 3854). The patient was examined in outpatient research clinic NII OMM Ministry of health of Russia 01.02.2011. Avtomobilnaya, powerseraya. Diagnosis: singleton pregnancy 7-8 weeks, burdened history of pregnancy (miscarriage in 2009), chronic cholecystitis in remission, nephroptosis on the right I-II century, the myopia of the I century, cervical erosion (cryosurgery in 2004). At the time of examination there are signs of threatened abortion (complaints dragging pain in the abdomen and blood discharge from the genital tract), the woman is a carrier of the gene mutation in folate metabolism: MTHFR AS - a/C (heterozygote). The laboratory examination of blood obtained the following indicators: the relative content CD54+lymphocytes - 25%, the level of lactoferrin - 2482 ng/ml, the concentration of β-HCG - of 8.9 ng/ml Prognostic index, calculated by the formula, equal -0,121, the negative value of the index indicates a high risk of implementation of gestational complications, and therefore the patient was referred to the risk of development of pathological conditions during pregnancy. In the period of 19 weeks of pregnancy by ultrasound and diplomaticheskogo studies have revealed the violation of the utero-placental circulation IA senior Woman was admitted to hospital, were observed and had received treatment in compliance and with the standard of medical care. In the period 29-30 weeks of pregnancy the woman was re-admitted to the hospital with subcompensated chronic placental insufficiency (premature maturation of the placenta) and threats of termination, were observed and had received treatment in accordance with the standard of medical care. The pregnancy ended in a self-urgent deliveries in the period 40-41 weeks. and the birth of live full-term girls with body weight 2450 g, a growth of 46 see the diagnosis of the child at birth: a syndrome of delayed fetal growth Art. I, gipoplasticheskaya option. Example 3. Makarova O.V. (history of births No. 2356). The patient was examined in outpatient research clinic NII OMM Ministry of health of Russia 22.04.2010. Avtomobilnaya, perforada. Diagnosis: singleton pregnancy 8-9 weeks, burdened obstetric history (medical abortion), obesity Art. II, arterial hypertension Art. I, myopia Art. II, the carrier of the herpes simplex virus, cytomegalovirus, symptoms of connective tissue dysplasia, cervical erosion. Signs of threatened abortion no, the woman is not a carrier of the gene mutations in folate metabolism. The laboratory examination of blood obtained the following indicators: the relative content D54+lymphocytes - 54%, the level of lactoferrin - 2847 ng/ml, the concentration of β-HCG - 14,38 ng/ml Prognostic index, R is schitannye by the formula, equal -3,923, the negative value of the index indicates a high risk of implementation of gestational complications, and therefore the patient was referred to the risk of development of pathological conditions during pregnancy. In the period 25-26 weeks gestation by ultrasound and diplomaticheskogo studies have revealed the violation of the utero-placental circulation And I tbsp., premature ripening placentae, oligohydramnios. The woman was admitted to hospital, were observed and had received treatment in accordance with the standard of medical care. The pregnancy ended operative delivery due to the weakness of labor activity at 41-42 weeks. and the birth of a live overdue boy weighing 3160 g, a growth of 51 see the diagnosis of the child at birth asphyxia, perenoshennosti. Example 4. Nikitin A.S. (history of births No. 1417). The patient was examined in outpatient research clinic NII OMM Ministry of health of Russia 09.12.2010. Avtomobilnaya, powerseraya. Diagnosis: pregnancy 7-8 weeks, burdened obstetric history (regressing pregnancy in a small time period, 1 medical abortion), the myopia of the I century, the media CMV, subclinical hypothyroidism in the stage of compensation, hyperandrogenism, overweight, chronic cholecystitis in remission, chronic pancreatitis in remission. Signs of pre threat is ivania pregnancy are not available, the woman is a carrier of the gene mutations in folate metabolism: MTRR A66G - A/G (heterozygote), MTHFR ST - S/T (heterozygote), MTHFR AS - a/C (heterozygote). The laboratory examination of blood obtained the following indicators: the relative content CD54+lymphocytes - 21%, the level of lactoferrin - 1050 ng/ml concentration (β-HCG - 28,68 ng/ml Prognostic index, calculated by the formula equal to 2,137, a positive index value indicates a low risk implementation of gestational complications. Upon further observation, according to the ultrasonic and diplomaticheskii studies during pregnancy the condition of the placenta and fetus were assessed as normal, the corresponding gestational age, pregnancy ended self-urgent deliveries in the period 40-41 weeks. and the birth of a live full-term baby boy weighing 3710 g, growth 54 see the diagnosis of the child at birth healthy. Example 5. Gribushin O.A. (history of births No. 1347). The patient was examined in outpatient research clinic NII OMM Ministry of health of Russia 27.12.2010. Parvovirinae, perforada. Diagnosis: pregnancy 12-13 weeks, subclinical hypothyroidism in the stage of compensation, vegetovascular dystonia of hypotonic type, myopia Art. III, chronic pyelonephritis in remission, chronic cystitis in remission. Signs of threatened abortion from wdtout, the woman is a carrier of the gene mutation in folate metabolism: MTRR A66G - G/G (heterozygote). The laboratory examination of blood obtained the following indicators: the relative content CD54+lymphocytes - 19%, the level of lactoferrin - 1899,5 ng/ml, the concentration of β-HCG - 24,13 ng/ml Prognostic index, calculated by the formula equal to 1,175, a positive index value indicates a low risk implementation of gestational complications. Upon further observation, according to the ultrasonic and diplomaticheskii studies during pregnancy the condition of the placenta and fetus were assessed as normal, the corresponding gestational age, pregnancy ended self-urgent deliveries in the period 39-40 weeks. and the birth of a live full-term baby boy weighing 3700 g, a growth of 53 see the diagnosis of the child at birth healthy. Clinical examples show that the violation of cell-mediated and humoral immunological mechanisms of regulation in the early stages of pregnancy, accompanied by the change of production of the main hormone, reflecting the proliferation of cytotrophoblast (β-HCG), along with the data of anamnesis women who are risk factors for the development of pathological conditions (presence/absence of the threat of termination of this pregnancy and carriage gene polymorphisms in folate metabolism) what is the pathogenetic basis implementation further gestational complications. The above confirms the predictive value of the proposed method. Thus, the inventive method of early prediction of implementation of gestational complications in comparison with known has the following advantages. 1. The method is minimally invasive, because the prediction is performed according to a study in the peripheral blood and records of medical history/examination. 2. The method allows to predict the risk of implementation of gestational complications with the use of a complex predictors, reflecting the effectiveness of regulatory mechanisms aimed at preserving and successful progression of pregnancy and is involved in the pathogenesis of various pathological conditions, regardless of the duration of pregnancy and nosological units (abortion by type underdeveloped or spontaneous abortion, placental insufficiency, delayed fetal growth and other perinatal pathology). 3. The proposed method allows early periods of gestation (pregnancy) to identify the risk group for the implementation of gestational complications, which enables the implementation of preventive measures aimed at prevention of pathological pregnancy. Sources of information taken into account in the examination: 1. Dry GT Immune factors in the etiology and pathogenesis of complications of pregnancy / Getsuga, Luvana // Obstetrics and gynecology. - 2012. No. 1. - S-136. 2. Kudryashov A.V. Role of the immune system in the formation of intrauterine development of the fetus / Avicularia, Neurotica, Lowposition, Iaanoaa, Muveenow // Ivanovo, 2009. - 240 S. 3. Panova I.A. Way to predict the outcome of pregnancy when the risk of miscarriage late / Iaanoaa, Neurotica, Navkratia, Aviva // Patent RU No. 2475752 from 20.02.2013. 4. Orlov A.V. Method of predicting pregnancy outcomes / Avilov, Tolbatova, Evilenko, Tbelieve, Othercanon // Patent RU No. 2268466 from 20.01.2006. 5. Retz J.V. Method of predicting pregnancy / Uwic, Gaushala, Dpetrov // Patent RU No. 2290861 from 10.01.2007. 6. Klimenkov S.A. Method of early prediction of obstetric risk / S.A. Klimenkov // Patent RU No. 2401069 from 10.10.2010. 7. Chistyakov GN. A method for predicting the development of placental insufficiency during pregnancy / Genkidama, Hahaganah // Patent RU No. 2300770 from 10.06.2007. 8. Titov, L.P. Method of predicting pregnancy outcome in women with recurrent pregnancy loss / Lpitem, Uwill-Chernomorets, Anelka / Patent RU No. 2033608 from 20.04.1995. 9. Hitova MB Forecasting, diagnosis and treatment of complications of pregnancy in women with high perinatal risk: author. Diss.... MD - Moscow, 2010 - 42 C. 10. Moiseeva V Method of predicting pregnancy outcome in women with a threatening miscarriage early / L.V. Moiseeva, EL Boyko // Patent RU No. 2103686 from 27.01.1998. 11. Barseghyan O.K. Method of predicting pregnancy outcome in women with a threatening miscarriage / Achberger, Neurotica, Avicularia // Patent RU No. 2033607 from 20.04.1995. 12. Tyre SCI non-developing pregnancy against herpes infection: pathogenesis, diagnosis, prevention: author. Diss.... CMN - Omsk, 2008 - 22 C. 13. Dubrovina S.O. a Method for predicting miscarriage early pregnancy infectious Genesis / Soubbotina, Ammalu // Patent RU No. 2444734 from 10.03.2012. 14. Saidov R.A. Informative hormone levels in early pregnancy for the diagnosis of non-developing pregnancy in women with hyperandrogenism / Rashidova, SSHUserName, Spilomyia, Use // Herald of the Russian obstetrician-gynecologist. - 2011. No. 4. -P.4-7. 15. Levkovich M.A. the Role of immuno-hormonal interactions in the Genesis of the threat of termination of early pregnancy / Mahavavy, Whaling, Voandzeia, Theget, EDV // Obstetrics and gynecology. - 2012. - Special issue. - P.3-7. 16. Makarov O. a Method for predicting high risk of relapse non-developing pregnancy in couples / Overow, Dagayev, Nah, Averman the HIV Lehmanniana // Patent RU No. 2454669 from 27.06.2012. 17. Putilova N.V. Method of prediction of pregnancy complications in women with thrombophilia / Navutulevu, Navbarname, Adisura // Patent RU No. 2429478 from 20.09.2011. 18. Rymasheuski A.N. A method for predicting the intrauterine development of the fetus in the 2nd trimester in HIV-infected / Animalistic, Averruncus // Patent RU No. 2435515 from 10.12.2011. 19. Bashmakova N.V. a method for predicting the intrauterine development of the fetus during pregnancy after assisted reproductive technology / Navbarname, Umirauscego, Nerabosnia-Basok, Kasmalieva, Adisura // Patent RU No. 2444995 from 20.03.2012. 20. Klimenkov S.A. a Method for predicting pathological pregnancy outcomes / Sagledano, Antlasman // Patent RU No. 2240722 from 27.11.2004. 21. Krukier I.I. method for the diagnosis of growth retardation of the fetus / IIA, Tintoreria, ACA, Evereska, Ann, Nagrobki, Atividade // Patent RU No. 2425379 from 27.07.2011. The method of early prediction of implementation of gestational complications, characterized in that from early pregnancy to determine the existence of any threat to abort this pregnancy and gene mutations in folate metabolism, evaluate the relative content of CD54+lymphocytes, the level of lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) in ve is Osney the blood of women calculate the prognostic index (PI) according to the formula:
|